Protagonist Therapeutics, Inc. (PTGX) Stock Grade

About Protagonist Therapeutics, Inc.'s fundamentals

Protagonist Therapeutics is a biotechnology company with a market capitalization of $9.2 billion and a P/E ratio of 17.0, though this valuation metric reflects the company's unprofitable status. The company experienced a severe 89.4% year-over-year revenue decline and posted a net margin of -282.8%, indicating substantial operating losses in its latest annual period. Despite these accounting losses, the company maintained positive free cash flow, suggesting it is managing its cash expenditures effectively, though this may reflect non-cash charges or timing of expenses rather than operational profitability. The company does not pay a dividend.